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1. Introduction
Bladder  carcinoma is  the  sixth  most  common cancer  worldwide with increasing health‐
care  burden  and  treatment  costs  [1-3].  The  majority  (70%)  of  bladder  cancers  are  su‐
perficial  tumours  which  require  close  observation  with  repeat  cystocopy,  timely
resection  and  long  term follow-up.  Of  these  superficial  bladder  cancers,  10% are  carci‐
noma in situ [4].
Originally described by Melicow in 1952 [5], carcinoma in situ(CIS) of the bladder is defined
as a flat (e.g. non-papillary) high-grade non-invasive urothelial carcinoma (transitional cell
carcinoma) [6]. An important distinction is that CIS of the urinary bladder, unlike testicular
and prostatic CIS, ‘in situ’ disease is not a precursor to malignancy but is a malignant entity
in its own right [6, 7] which has over 50% five-year progression rate in untreated disease
and higher recurrence rates [8, 9].
CIS is characterised by a flat ‘red velvet’ lesion which is usually multifocal and predomi‐
nantly found in the trigone region, peri ureteral areas and the bladder neck with frequent
involvement of the posterior and lateral walls [10]. Extra-vesical CIS is frequently found in
the ureters and prostatic urethra.
The  microscopic  features  of  CIS  (Figure  1)  are  nuclear  anaplasia  (identical  to  that  of
high  grade  urothelial  carcinoma)  containing  large  irregular,  hyperchromic  nuclei  (3  to
5  times  the  size  of  a  lymphocyte)  and  frequent  mitotic  activity  and  usually  observed
in  part  of  or  the  entire  thickness  of  epithelium  in  the  mid  to  upper  urinary  tract  [11,
12].  Immunohistologically,  these  cells  also  stain  diffusely  positive  for  CK20  and  ex‐
presses p53 [11].
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Figure 1. This figure demonstrates the histological features of CIS.
2. Classification of CIS
CIS was previously categorised under the broad term ‘moderate/severe dysplasia or marked
atypia’ [11] where the grade was determined by the degree/severity of dysplasia. However,
the grading of bladder cancers has been subject to much controversy and a more compre‐
hensive classification system was published by the World Health Organisation and the In‐
ternational Society of Urological Pathology (WHO/ISUP) in 1998 [13]. The current WHO/
ISUP classification states that ‘by definition, all CIS are high-grade lesions. CIS should not be sub
classified by grade, despite the spectrum of pleomorphism seen within this entity’ [11].
The TNM bladder cancer staging system also acknowledges CIS as a separate entity (Tis);
however, it is classified along with the low grade Ta and T1 tumours in bladder tumours.
Different classifications have been suggested in order to stratify risk and prognosis of CIS.
One of the methods used to determine the prognosis of CIS was by the presence of symp‐
toms, number of sites of involved (multifocal vs. unifocal) and concurrent CIS with papillary
tumours. However these features have not been completely validated [7].
A currently used classification of CIS [7, 10, 14] is:
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• Primary (isolated lesion in the bladder urothelium with no previous or concurrent papil‐
lary tumours).
• Secondary (CIS detected during the follow-up of patients with a previous papillary tu‐
mour).
• Concurrent (CIS in the presence of papillary tumours).
Primary CIS has a worse outcome with higher rates of progression to muscle invasive dis‐
ease resulting in a higher rates of cystectomy; but is shown to respond better to BCG thera‐
py compared to secondary CIS [15]. A further study confirmed the higher rates of
progression to muscle invasive disease in primary CIS, while concurrent CIS was shown to
have the worst survival rates [16]. This highlights the importance of differentiating between
the types of CIS in determining the prognosis and also identifying primary CIS early.
3. Incidence
Although increases in the incidences of bladder cancer in the USA, Japan and European
countries have been observed in recent decades [1, 2], the incidence of primary CIS remains
largely unknown. This is mainly due to bladder CIS being classified as a ‘premalignant con‐
dition’ with other ‘in situ’ diseases and therefore is a non-reportable condition in many
countries. An excellent example is that CIS and pTa bladder carcinomas are registered
alongside malignant disease in North America but not the UK [17]. However, more cancer
registries are recommended to include CIS as a reportable malignancy, as these ‘unreported’
increasing incidences can sometimes go unnoticed [18].
The literature suggests that between 5-10% of bladder carcinomas are CIS but this could be
as high as 19 % [14]. Our analysis of the Surveillance Epidemiology and End Result (SEER)
database [19] revealed an incidence of 14 per 100,000 persons where CIS was the primary
coded tumour from 1973 -2009. The incidence of CIS in males and females in the US were
24.9 and 6.2 per 100,000, respectively. In comparison the incidence of malignant bladder can‐
cer was 27 per 100,000 in males and 6.8 per 100,000 in females, for the same duration. In ad‐
dition, there was a 28% increase in the overall incidence of CIS from 1975, with 27% and 20%
seen in males and females respectively. On a Joinpoint regression analysis [20], there was a
significant 0.3% annual percentage increase in males since 1990, but not in females. It should
be noted that these CIS rates could also include secondary and concurrent CIS.
In Australia the incidence of primary CIS was 20.9 per 100,000 and 6.5 per 100,000 in males
and females >50 years respectively, with an 11% and 14% annual increase seen from 2001
onwards [18].
There could be significant variation in the reported incidence of CIS in cancer registry data
due to a variety of factors such as inter- observer variability in categorisation of the tumour,
coding differences and increasing awareness of CIS. Similarly, re-resection of the tumours
can upstage an initial diagnosis of a tumour. In addition, being an unreported malignancy,
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there is significant emphasis being placed on the hospital coding to determine the incidence
of CIS and it can also be difficult to determine if the diagnoses coded as CIS are histological‐
ly proven post biopsy or if they are based on cytology alone. Furthermore, increasing aware‐
ness with higher screening or investigation rates could play an important role in increased
number of diagnoses of CIS.
These factors provide some limitations for determining the actual incidence of CIS. Howev‐
er, importance of recording the trends of CIS is essential and may help observe for any in‐
creases in incidence and initiate awareness and early intervention.
4. Risk factors
4.1. Gender and age
Male gender is a well documented risk factor in bladder cancer with males having a 4.1
fold increase compared to females [1]. As with bladder carcinoma, male gender tends to
have  a  higher  preponderance  for  CIS  than  females  with  3.1-7  times  risk  of  developing
CIS [18, 21, 22].
Increasing age is also a risk factor for bladder cancer. The highest incidences of bladder can‐
cer are seen in the >50 year olds [23] while the mean incidence for patients with CIS also oc‐
curs between the ages of 65-73 years [21, 22].
4.2. Smoking
Smoking is one of the major risk factors for bladder cancer. Smoking increases the risk of
bladder cancer by 2- 6 fold which is augmented by increasing duration and frequency of
smoking, while cessation of smoking decreases this risk [2]. The effects of long term smok‐
ing are found to carry similar risks for developing bladder cancer in both sexes [24].
Although not many studies have focussed exclusively on the relationship of CIS and smok‐
ing, there is evidence to establish smoking as a risk factor for CIS. In a study which focussed
only on CIS, the 72% of patients who presented with CIS were either former or current
smokers [15]. In a another study of all superficial bladder tumours, which included CIS,
showed that those who continued to smoke after the diagnosis of the tumour, had worse
bladder cancer related outcomes with a shorter time to disease recurrence, while ex-smokers
tended to present with a tumour at a later age [25]. However, the link between smoking and
failure of BCG therapy bladder tumours is not very clear [26].
Despite the strong links between smoking and bladder cancer, smoking can only partially
account for the incidence of bladder cancer suggesting that other risk factors also contribute
to the risks [27].
Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment72
4.3. Schitosomiasis infection
Schistosoma haematobium or Bilharzia is  a  known pathogen for causing bladder cancer
in the prevalent areas and accounts for about 3% of the world bladder cancer [2].  Infec‐
tion with schistosomiasis increases the risk of bladder cancer by 5 fold and accounts for
majority of the incidence squamous cell bladder cancers [2]. However, CIS has been also
seen  in  patients  with  Schistosomial  infection  where  the  pathogenesis  is  thought  to  be
linked to chromosomal loss [28].
4.4. Occupational carcinogens
There is a well established link between occupational carcinogen and bladder cancer with an
estimated 20- 27% of bladder cancers attributed to occupational exposures. The main carci‐
nogens associated with industrial occupational risk are aromatic amines (beta-naphthyla‐
mine, 4-aminobiphenyl and benzidine) which are used widely as intermediary compounds
in the textile and rubber industries. The risk of occupational bladder cancer is dependent not
only on the intensity and characteristics of the workplace exposures, but also on individual
susceptibility to these cancers [29]. Similar to bladder carcinoma, CISs also develops in pa‐
tients exposed to these carcinogens [30] where mutations of the p53 gene is thought to ini‐
tiate the disease process [31]
4.5. Genes
Polymorphisms in the genes, NAT2 and GSTM1 are the main genetic modulations implicat‐
ed in the bladder cancer. NAT 2 encodes the N-acetyltransferase 2 enzyme responsible for
detoxification of aromatic amines by N-acetylation or activation by O-acetylation, while
GSTM1 encodes the glutathione S-transferase M1 enzyme responsible for detoxification of
carcinogens such as polycyclic aromatic hydrocarbons and reactive oxygen species. [32] In
CIS however, the genetic mutations are different and characterized by loss-of-function of the
tumour suppressor genes, such as p53, RB, and PTEN [33]. These genetic changes are dis‐
cussed in detail in another chapter.
4.6. Diet
Dietary factors are also shown to be linked to bladder cancer. Fruit and vegetative intake
correspond inversely with the risk of bladder cancer while there is evidence to show that
Vitamin B and yellow orange vegetables (in individuals with the presence of GSTM1) may
also reduce the risk of bladder cancer [32]. However, to our knowledge, there are no specific
studies looking at the dietary risks and CIS.
5. Presentation
Presentation of primary CIS of the bladder can be very variable (Table 1). Majority of the
patients with primary CIS present with only non-specific irritative bladder symptoms such
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as dysuria, frequency, urgency or nocturia [15] [21, 22, 34]. Furthermore up to 22- 26% of
patients are asymptomatic and less commonly may present with suprapubic fullness or
pain, back or flank discomfort, lower abdominal pain, or pelvic-perineal pain [15, 21, 22]. In
contrast with bladder cancer, fewer than 45% of the patients have macroscopic or micro‐
scopic haematuria in primary disease [22], highlighting the difficulty in diagnosing this con‐
dition. In contrast, the patients with secondary or concomitant CIS tend to present with
gross haematuria, possibly due to the presence of a papillary tumour [15].
Symptom
% with symptom
Primary CIS Secondary/concomitant CIS
Irritative 28.5(15) 9.8(15)
Asymptomatic 22(15)- 26(22) 21(15)
Macroscopic haematuria 31.2(15) 50.6(15)
Table 1. The percentage of patients presenting with various symptoms of primary and secondary/concomitant CIS.
6. Diagnostic workup
6.1. Biopsy of the red velvet lesion
The diagnosis of CIS can be challenging task due to the flat nature of the lesion, where
the mucosa containing the lesion could be unremarkable or simply an erosion [21]. There‐
fore,  biopsy  of  the  lesion  is  the  current  advocated  method  for  diagnosis  of  CIS  of  the
bladder. However, even the characteristic ‘red velvety patch’ of CIS could be non-specific
[21] and the specificity could be as low as 8% [35]. Thus it is recommended that the biop‐
sies of even the normal mucosa are taken in high risk patient or in the presence of posi‐
tive cytology [14, 21].
In addition, a second look transurethral resection (TUR) and bladder mapping biopsies are
frequently warranted to reduce under staging, exclude residual disease and concurrent CIS
in patients with other bladder tumours [15].
6.2. White light cystoscopy vs. fluorescent light cystoscopy
One of the difficulties during cystoscopy is the visualisation of this flat lesion in the bladder,
which could be inconspicuous under normal white light cystoscopy and can be missed re‐
sulting in significantly under-reporting. The recent use of fluorescent light cystoscopy using
5-aminolevulinic acid or hexaminolevulinate has been shown to enhance the detection of
CIS by more than 30%- 39% [36, 37] and also to reduce tumour recurrence at 1 and 2 years
[38]. When using florescent light cystoscopy, both 5-aminolevulinic acid and hexaminolevu‐
linate are shown to be equally effective at detecting CIS [37]. In addition, the use of HAL
when resecting tumours is shown to reduce tumour recurrence in CIS and also in multifocal
Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment74
tumours [39]. Despite the benefits of fluorescent light cystoscopy, one of its major draw‐
backs is the high false positive rates. The European Urology Association guidelines recom‐
mendations of the use of fluorescent light cystoscopy due to its high sensitivity [14], but it is
not universally used in practice due to availability and cost implications.
6.3. Biomarkers
Biomarkers have been widely used in aiding the detection of CIS. Some of the routinely
used biomarkers are urine cytology, UroVysion (fluorescent in-situ hybridization - FISH),
immunocytology and Nuclear Matrix Protein (NMP22). Of these, urine cytology is the most
frequently used in detecting CIS due to its high sensitivity. However the specificity of cytol‐
ogy, FISH and immunocytology are all below 30% limiting the diagnostic accuracy of CIS
[40]. Even, NMP22 which has the highest specificity for CIS, is only 43% [40] (Table 2).
Modality Percentage CIS detected
Biopsy of ‘red mucosa’ 8-78%(44), (35)
Florescent light cystocopy (using 5-aminolevulinic acid or
hexaminolevulinic acid) 92.4%(45).
White light cystoscopy 60.5%(45)
Urine Cytology 90% - 92.3(6, 40)
UroVysion (fluorescent in-situ hybridization - FISH) 83.6(40)
Immune-cytology µCyt 81.3(40)
NMP22 79.1(40)
Combination of FISH+ CYT 85.3(40)
Table 2. The percentage of CIS detected by each modality of testing.
Therefore to optimise the accuracy of diagnosis, it is recommended that these biomarkers
should be used in conjunction with each other rather than on their own [21]. The use of cy‐
tology and NMP22 together increase the specificity 55% and using all 4 modalities increase
the sensitivity to 65% [40]. However, due to lower sensitivities of some of these tests, the
overall sensitivity decreases as more tests are combined [40]. Therefore an optimum balance
must be used to obtain the best sensitivity and specificity values in diagnosis of CIS.
Another very useful role of biomarkers is to predict response to treatment. A number of
biomarkers, urine markers and genetic markers have been evaluated to predict which tu‐
mours will fail BCG therapy [41]. Interleukin -2 is shown to be promising in in identify‐
ing the tumours which will not respond to BCG therapy. However, currently none of the
other markers have large studies or long term validation to predict treatment failure pri‐
or to starting BCG [41].
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6.4. Screening for CIS
The usefulness of biomarkers as screening tools in detection of CIS is suboptimal. A study
which screened a group of 183 smokers using a variety of screening tools, showed the true
positive rates for detection of malignant tumours were only 50% for Dipstick, 6% for Blad‐
derChek, 37% for cytology and 61% for UroVysion (FISH) [42]. The 2 patients with CIS, had
negative results for urine dipstick and cytology but were positive for UroVysion [42]. How‐
ever, another study showed low cost effectiveness of the use of Uro Vysion as a screening
tool, due to its high costs [43]. Thus screening for CIS may not be economically viable.
7. Treatment
Studies have demonstrated that the untreated natural history of CIS has a 50% progression
rate to malignant disease at 5 years and even with optimal treatment, progression and recur‐
rence rates are both high [8, 9].
7.1. Tumour resection
Transurethral resection (TUR) is essential in providing histological tissue and reducing the
tumour load. When the muscularis mucosa is involved, a re-resection is usually necessary.
Despite this, in treatment of CIS, solitary TUR is shown to be inferior compared to TUR
when used in conjunction with BCG, with the latter having increased the 10 year progres‐
sion free survival (71% vs. 50%) [46].
7.2. Intravesical Chemotherapy/Immunotherapy
Intravesical instillation of a chemotherapeutic/immunotherapeutic agent is the mainstay
treatment for CIS. A number of agents such as Bacille Calmette-Guerin (BCG), mitomycin C,
epirubicin, doxorubicin and adriamycin have been trialed. In comparison trails between
these agent, BCG is shown to be superior to other chemotherapeutic agents with higher
complete response rates (68% vs. 49%) and higher disease free rates (51% vs. 27%) [14]. Fur‐
thermore, the use of BCG with maintenance therapy was also superior to mitomycin C [47].
Despite the advantages of BCG therapy, studies have demonstrated that 20% to 40% fail to
respond and progress [41]. In addition, up to 90% of patients experience side effects such as
local cystitis symptoms such dysuria, frequency alteration, and occasional haematuria re‐
sulting a number of patients not completing the treatment schedule [41].
7.3. Radio therapy
Radiotherapy is a is also used as a treatment modality in bladder carcinoma, where radi‐
otherapy is shown to complete local regression of muscle-invasive bladder cancer in up‐
to 73% of patients [48].  However radiotherapy has been shown to be ineffective against
CIS of the bladder. In CIS patients treated with EBRT have demonstrated persistent CIS
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after treatment and was shown to be inferior to radical cystectomy [49, 50]. Furthermore
in patients with concomitant CIS treated with radiotherapy, the presence of CIS carried a
worse prognosis [51].
7.4. Cystectomy
Cystectomy is an important option in treating CIS of the bladder due to its high cure rates in
high risk patients [52] and is advocated in high risk patients. This is especially useful in pa‐
tients who do not respond to BCG, where early cystectomy is shown to improve long term
survival [53]. However, studies have shown that the presence of CIS to be an independent
risk factor for upper tract recurrence in patients who undergo cystectomy [54]. In patients
with prostatic urethral involvement, immediate or delayed urethrectomy is advocated [55].
7.5. Photodynamic therapy
Photodynamic therapy works by light of a specific wavelength that is absorbed by a chemi‐
cal photosynthesizer, which then transfers this energy to breakdown oxygen molecules into
highly reactive intermediates [56]. An advantage of photodynamic therapy is that the whole
bladder mucosa can be treated without having to localise multifocal superficial bladder tu‐
mours and occult CIS. A number of photo synthesizers have been used such as Hematopor‐
phyrin derivatives and 5-aminolevulinic Acid (ALA). Photodynamic therapy has been
shown to be very promising results in treating CIS, and may provide an alternative treat‐
ment for resistance disease [56].
7.6. Treatment for Non-intravesical CIS of the bladder
Extra vesical CIS of the bladder is seen most frequently in the ureters and in the prostatic
urethra. In upper tract CIS, BCG therapy is shown to be very effective [57] and the long term
data is seen to be as effective as nephroureteroctomy [58]. However, patients who undergo
radical nephrectomy and have upper tract concomitant CIS have higher rates of recurrence
and poorer cancer specific survival [59].
BCG therapy is also effective in patients with CIS of the prostatic urethra and transurethral
resection is thought to have no added advantage [60] However, presence of CIS of the pro‐
static urethra carries a poorer prognosis and in primary high grade bladder cancers treated
with BCG, it is recommended that the prostatic urethra is biopsied as it is a prognostic factor
for recurrence, progression of disease and bladder cancer specific mortality [61]. Presence of
CIS of the prostatic urethra is also an indication for early cystectomy [62].
7.6.1. Current recommendations for CIS
7.6.1.1. Treatment of primary CIS
The American Urology Association (AUA) guidelines [63] recommend re-resection in high
grade disease in the absence of muscularis propria in the specimen as standard treatment
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followed by an induction course of BCG and maintenance BCG therapy. They suggest that
cystectomy also maybe an option in select CIS patients due to high cure rates.
The European Association of Urology (EAU) guidelines [64] state that the BCG installation
should be administered for at least 1 year and if the prostatic urethra is involved, TUR of the
prostate followed by BCG therapy is recommended for the management of CIS. Unlike the
AUA guidelines, cystectectomy is only reserved for BCG failure due to concerns of over‐
treatment. They suggest 3 monthly follow up cytology with cystoscopy for 2 years and ev‐
ery 6 months thereafter until 5 years followed by annually thereafter. Annual upper tract
imaging is also recommended.
7.6.1.2. Treatment of recurrent disease
The AUA guidelines [63] recommend repeat resection in order to aid accurate staging as
standard treatment and also recommend cystectomy as an option due to high risk of pro‐
gression to muscle invasive disease in these patients. They suggest that further intravesical
therapy maybe an option.
The EAU [64] guidelines suggest that although further BCG instillation can be beneficial in
non-muscle invasive recurrence post chemotherapy, it increase the risk of progression in CIS
and they recommend the use of early cystectomy following BCG failure in suitable patients.
They further acknowledge that although device assisted chemotherapy instillation and use
of concomitant interferon alpha maybe beneficial in select patients, they feel that they are
still experimental.
In conclusion, this chapter discusses the incidence, diagnostic difficulty and management of
CIS and also the current recommended guidelines.
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